Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.53M | -11.18M | -36.72M | -44.77M | -56.30M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.22M | -31.87M | -805.00K | 4.35M | 8.30M |
| Change in Net Operating Assets | -2.27M | 5.94M | -9.04M | -568.00K | 10.80M |
| Cash from Operations | -44.58M | -37.12M | -46.56M | -40.99M | -37.20M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -7.00M | 0.00 | 7.00M | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -240.41M | 25.00M | 72.00M | -61.00K | -170.54M |
| Cash from Investing | -247.41M | 25.00M | 79.00M | -61.00K | -170.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 312.88M | 491.00K | 731.00K | 335.00K | 225.93M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -69.00K | -5.13M | 0.00 | -210.00K | -328.00K |
| Cash from Financing | 312.81M | -4.64M | 731.00K | 125.00K | 225.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -15.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.82M | -16.76M | 33.17M | -40.93M | 17.84M |